Alterola Biotech, Inc.
Alterola Biotech, Inc. (ABTI) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
abti · pe ratio · data through Mar 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Alterola Biotech, Inc. (ABTI) measures how much investors pay for each dollar of the company's trailing earnings. ABTI's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$0.00.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-03-31
PE Ratio History
2009 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Alterola Biotech, Inc.You ABTI | $7M | N/A | — | -$0.00 |
 Benchmark Holdings plc BHCCF | $225M | N/A | — | -$0.05 |
 Craftport Cannabis Corp. BHHKF | $0M | N/A | — | -$0.49 |
 Cellectis S.A. CMVLF | $251M | N/A | — | -$0.70 |
 Cipher Pharmaceuticals Inc. CPHRF | $307M | 10.06x | — | $1.09 |
 3-D Matrix, Ltd. DMTRF | $270M | N/A | — | -$25.20 |
 Spectral Medical Inc. EDTXF | $279M | N/A | — | -$0.17 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-03-31Latest FY2023 | — | $-0.00 | — | |
2022-03-31 FY2022 | — | $-0.01 | — | |
2020-09-30 FY2020 | — | $-0.00 | — | |
2019-09-30 FY2019 | — | $-0.00 | — | |
2018-09-30 FY2018 | — | $-0.00 | — | |
2017-09-30 FY2017 | — | $-0.00 | — | |
2016-09-30 FY2016 | — | $-0.00 | — | |
2015-09-30 FY2015 | — | $-0.00 | — | |
2014-09-30 FY2014 | — | $-0.00 | — | |
2013-09-30 FY2013 | — | $-0.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Alterola Biotech, Inc. (ABTI) measures how much investors pay for each dollar of the company's trailing earnings. ABTI's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$0.00.
Frequently asked questions
ABTI pe ratio · 6 questionsABTI's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.01 and TTM EPS of -$0.00. Data sourced from Financial Modeling Prep via ABTI's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Alterola Biotech, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09